Posted On: 11/30/2014 1:56:44 PM
Post# of 53
Will be watching for that upside to unfold this way
$CAPR
Capricor announced that the company’s lead therapeutic candidate, CAP-1002, will be evaluated in an additional indication, Duchenne Muscular Dystrophy (DMD). The new program is based on preclinical data scheduled for presentation at the American Heart Association’s (AHA) Scientific Sessions on November 17. We believe the new indication area, which expands Capricor’s pipeline beyond the ischemic heart failure market, represents an expansion of the company’s pipeline.
Website
On Low Floats Sticky
Shares Outstanding: 11.70M
Float: 3.39M
$CAPR
Capricor announced that the company’s lead therapeutic candidate, CAP-1002, will be evaluated in an additional indication, Duchenne Muscular Dystrophy (DMD). The new program is based on preclinical data scheduled for presentation at the American Heart Association’s (AHA) Scientific Sessions on November 17. We believe the new indication area, which expands Capricor’s pipeline beyond the ischemic heart failure market, represents an expansion of the company’s pipeline.
Website
On Low Floats Sticky
Shares Outstanding: 11.70M
Float: 3.39M
(0)
(0)
